Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENHERTU vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Unresectable or metastatic HER2-positive breast cancer after prior anti-HER2-based regimen in metastatic setting,Metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer after prior chemotherapy in metastatic setting,Unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after prior trastuzumab-based regimen,HER2-positive non-small cell lung cancer with activating HER2 mutation after prior systemic therapy,HER2-positive solid tumors (tumor agnostic) after prior systemic therapy and no satisfactory alternative
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
DXd, the released payload, is primarily metabolized by CYP3A4.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Trastuzumab deruxtecan: Approximately 99% bound to plasma proteins (primarily to albumin).
Approximately 20–30% bound to plasma proteins.
Approximately 10–12 L (approx. 0.14–0.17 L/kg for a 70 kg adult), indicating distribution primarily in vascular space.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Not applicable; administered intravenously (100% bioavailability).
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). No data for severe renal impairment (Cr Cl <30 m L/min).
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 4.4 mg/kg. Child-Pugh C: Not recommended.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established; no recommended dose.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment. Monitor for toxicity, especially in patients aged ≥65 years due to limited data.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY. Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have occurred. Monitor for signs and symptoms of ILD and withhold, dose reduce, or permanently discontinue based on severity. Exposure during pregnancy can cause embryo-fetal harm; advise patients of these risks.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Interstitial lung disease/pneumonitis,Left ventricular ejection fraction (LVEF) reduction,Neutropenia,Fever, infection, or thrombocytopenia,Embryo-fetal toxicity
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
None listed.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific food interactions are known; however, ENHERTU may cause nausea, vomiting, and diarrhea. Patients should avoid heavy, spicy, or fatty foods if gastrointestinal side effects occur and maintain adequate hydration.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of trastuzumab deruxtecan to pregnant rats during organogenesis resulted in embryofetal toxicity including decreased fetal weight and increased fetal malformations at exposures below the recommended human dose based on AUC. Due to the potential for genotoxicity and inhibition of rapidly dividing cells, there is a high teratogenic risk, particularly during the first trimester. During second and third trimesters, fetal growth restriction and oligohydramnios may occur due to HER2 receptor inhibition, although the deruxtecan component primarily drives toxicity. Effective contraception should be used during treatment and for at least 7 months after the last dose.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
There are no data on the presence of trastuzumab deruxtecan in human milk, its effects on the breastfed child, or milk production. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 7 months after the last dose. The M/P ratio is unknown.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
There are no specific dose adjustment guidelines for ENHERTU during pregnancy. The recommended dose is 5.4 mg/kg as an intravenous infusion every 3 weeks. Pregnancy may alter drug pharmacokinetics due to increased plasma volume, reduced albumin, changes in hepatic metabolism and renal clearance. However, no pharmacokinetic studies have been conducted in pregnant women. Therefore, the standard dosing should be used with caution, and clinical judgment should be applied based on maternal and fetal monitoring. Dose reductions or delays may be considered if significant toxicities (e.g., ILD, neutropenia, hepatic impairment) occur. Due to the high risk of fetal harm, use in pregnancy is not recommended unless the maternal benefit justifies the risk.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Monitor for interstitial lung disease (ILD) and pneumonitis; withhold ENHERTU for grade 1 ILD and permanently discontinue for grade 2 or higher. Assess left ventricular ejection fraction (LVEF) before and during treatment; withhold for any grade of reduction. Premedicate with antiemetics per institutional guidelines. Do not substitute with trastuzumab or ado-trastuzumab emtansine.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Report new or worsening cough, shortness of breath, or fever immediately as these may be signs of lung problems.,Notify your doctor of any nausea, vomiting, diarrhea, or constipation as these can be managed with medications.,Avoid pregnancy during treatment and for 7 months after last dose; use effective contraception.,Do not breastfeed during treatment and for 1 month after last dose.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENHERTU vs CLADRIBINE, answered by our medical review team.
ENHERTU is a Antineoplastic Agent that works by Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENHERTU and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENHERTU is: 5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENHERTU and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENHERTU is classified as Category C. Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.